Powder: -20°C for 3 years | In solvent: -80°C for 1 year
EMI48, a derivative of EMI1, exhibits increased efficacy against mutant EGFR compared to EMI1. It specifically inhibits EGFR triple mutants [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | 6-8 weeks | $ 259.00 | |
25 mg | 6-8 weeks | $ 893.00 | |
50 mg | 6-8 weeks | $ 1,160.00 | |
100 mg | 6-8 weeks | $ 1,650.00 | |
1 mL * 10 mM (in DMSO) | 6-8 weeks | $ 272.00 |
Description | EMI48, a derivative of EMI1, exhibits increased efficacy against mutant EGFR compared to EMI1. It specifically inhibits EGFR triple mutants [1]. |
In vitro | EMI48 effectively targets and inhibits the EGFR ex19del/T790M/C797S and EGFR L858R/T790M/C797S mutations, making it a valuable agent in the study of mutant EGFR-associated, drug-resistant non-small-cell lung cancer (NSCLC) [1]. |
Molecular Weight | 348.4 |
Formula | C21H20N2O3 |
CAS No. | 34564-13-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
EMI48 34564-13-1 inhibitor inhibit